Patrik SundströmNikita DuttaWilliam RodinAndreas HallqvistSukanya RaghavanMarianne Quiding Järbrinka Department of Microbiology and Immunology,Institute of Biomedicine,The Sahlgrenska Academy at University of Gothenburg,Gothenburg,Swedenb Department of Oncology,Institute of Clinical Sciences,The Sahlgrenska Academy at University of Gothenburg,Gothenburg,Swedenc Department of Oncology,Sahlgrenska University Hospital,Gothenburg,Swedend Department of Clinical Immunology and Transfusion Medicine,Sahlgrenska University Hospital,Gothenburg,Sweden

Abstract:Mucosal-associated invariant T (MAIT) cells constitute one of the most numerous unconventional T cell subsets, and are characterized by rapid release of Th1- and Th17-associated cytokines and increased cytotoxic functions following activation. MAIT cells accumulate in tumor tissue but show an exhausted phenotype. Here, we investigated if immune checkpoint blockade (ICB) with antibodies to PD-1 or PD-L1 affects the function of circulating MAIT cells from non-small cell lung cancer patients. ICB increased the proliferation and co-expression of the activation markers HLA-DR and CD38 on MAIT cells in most patients after the first treatment cycle, irrespective of treatment outcome. Furthermore, production of cytokines, especially TNF and IL-2, also increased after treatment, as did MAIT cell polyfunctionality. These results indicate that MAIT cells respond to ICB, and that MAIT cell reinvigoration may contribute to tumor regression in patients undergoing immune checkpoint therapy.

Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer